干扰素联合病毒唑治疗慢性乙型肝炎的临床疗效观察

目的观察分析干扰素联合病毒唑治疗慢性乙型肝炎的临床疗效以及安全性。方法回顾性分析我院于2012年5月—2013年6月收治的160例慢性乙型肝炎患者的病历资料,随机的分为对照组和治疗组,对照组和治疗组各80例,对照组中的80例慢性乙型肝炎患者采取单用干扰素治疗,治疗组中的80例慢性乙型肝炎患者采取干扰素联合病毒唑治疗,观察分析两组慢性乙型肝炎患者治疗前后的症状体征的改善程度、生化应答率、病毒应答率以及不良反应的发生情况。结果经治疗,对照组临床症状改善率为78%,病毒应答率为45%,生化应答率为72%。治疗组临床症状改善率为78%,病毒应答率为45%,生化应答率为72%,两组间治疗之后的临床症状改善率、病毒应答率以及生化应答率进行比较,P〉0.05,无统计学意义。对照组的持续应答率为17%,治疗组持续应答率为46%,两组间的持续应答率进行比较,P〈0.05,有统计学意义。结论干扰素联合病毒唑治疗慢性乙型肝炎临床疗效尤为显著,不仅仅将慢性乙型肝炎患者的抗病毒治疗疗效增强,同时又有着良好的耐受性,有着一定的可行性和安全性,值得临床推广。

To observe the clinical curative effect of interferon combined with ribavirin in the treatment of chronic hepatitis B

Objective To observe and analyze the interferon combined with ribavirin in the treatment of chronic hepatitis B clinical efficacy and safety. Methods A retrospective analysis of our hospital in 2012 May -2013 year in June 160 cases of chronic hepatitis B patients medical records, randomly divided into control group and treatment group, control group and treatment group with 80 cases in each group, 80 cases of chronic hepatitis B patients in the control group treated only with interferon in treatment group, 80 patients with chronic hepatitis B to interferon and ribavirin, observing the improvement degree of occurrence, clinical symptoms and signs of the two groups before and after treatment in patients with chronic hepatitis B virus biochemical response rate, response rate and adverse reaction of. Results After treatment, the control group in improving clinical symptoms was 78%, viral response rate was 45%, biochemical response rate 72%. The clinical symptom improvement rate was 78%, viral response rate was 45%, biochemical response rate was 72%, between the two groups after treatment, clinical symptom improvement rate, viral response rate and compared, biochemical response rate of P〉0.05, no statistical significance. The sustained response rate was 17%in control group, the treatment group the sustained response rate was 46%, the rate of sustained response between the two groups were compared, P 〈0.05, there was statistical significance. Conclusion Interferon combined with ribavirin for the treatment of chronic hepatitis B is very significant, not only will enhance the efficacy of antiviral therapy in patients with chronic hepatitis B,and has a good tolerance, the feasibility and safety of certain, is worth the clinical promotion.